Decoding Neurological Disease. Building Medicines.

CMT1A and related neurological disorders still have no approved disease-modifying therapies. We are working to change that by integrating deep disease biology and our proprietary PRECISION™ platform into a unified drug discovery engine.

A New Paradigm in Neurotherapeutics
We are building a new approach to neurological drug discovery, integrating real disease biology and AI to help identify molecules with stronger translational potential.

Targeting CMT1A Root Cause
We are advancing a mechanistically distinct pipeline of precision therapies for CMT1A, the most common inherited peripheral neuropathy. Our therapeutics are designed to target core disease pathology and support peripheral nerve function.

Where Biology Meets AI
Our PRECISION™ platform captures high-content phenotypic data across an extensive compound library using proprietary disease-relevant models. This exclusive biological dataset powers our AI to generate actionable phenomic signatures that guide drug discovery.

Partner With Us
We are building strategic alliances to accelerate our CMT1A programs and expand the reach of our PRECISION™ AI platform.

Join the Team
Build the future of precision medicine at the intersection of neuroscience and AI.

A New Paradigm in Neurotherapeutics We are building a new approach to neurological drug discovery, integrating real disease biology and AI to help identify molecules with stronger translational potential.

Targeting CMT1A Root Cause We are advancing a mechanistically distinct pipeline of precision therapies for CMT1A, the most common inherited peripheral neuropathy. Our therapeutics are designed to target core disease pathology and support peripheral nerve function.

Where Biology Meets AI Our PRECISION™ platform captures high-content phenotypic data across an extensive compound library using proprietary disease-relevant models. This exclusive biological dataset powers our AI to generate actionable phenomic signatures that guide drug discovery.

A New Paradigm in Neurotherapeutics
We are building a new approach to neurological drug discovery, integrating real disease biology and AI to help identify molecules with stronger translational potential.

Targeting CMT1A Root Cause
We are advancing a mechanistically distinct pipeline of precision therapies for CMT1A, the most common inherited peripheral neuropathy. Our therapeutics are designed to target core disease pathology and support peripheral nerve function.

Where Biology Meets AI
Our PRECISION™ platform captures high-content phenotypic data across an extensive compound library using proprietary disease-relevant models. This exclusive biological dataset powers our AI to generate actionable phenomic signatures that guide drug discovery.